Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 5/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 12/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3234541 | 0.98 | CASR (0.44) | CASREPHX2POLBCD274 | |
| SCHEMBL3232291 | 0.89 | EPHX2 (0.47) | CASREPHX2POLBCD274 | |
| SCHEMBL4219747 | 0.89 | CD274 (0.41) | EPHX2POLBCD274 | |
| SCHEMBL3229630 | 0.88 | EPHX2 (0.42) | EPHX2CD274 | |
| SCHEMBL3223625 | 0.88 | EPHX2 (0.42) | EPHX2CD274 | |
| SCHEMBL3230179 | 0.88 | JAK2 (0.38) | CASREPHX2POLBCD274 | |
| SCHEMBL3218892 | 0.87 | QPCT (0.41) | EPHX2CD274 | |
| SCHEMBL3230756 | 0.87 | EPHX2 (0.46) | CASREPHX2POLBCD274 | |
| SCHEMBL3225953 | 0.87 | EPHX2 (0.45) | EPHX2CD274 | |
| SCHEMBL4224300 | 0.86 | RAB9A (0.41) | EPHX2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056522-A1 | INTRAOCULAR PRESSURE-LOWERING AGENT COMPRISING COMPOUND HAVING HISTONE DEACETYLASE INHIBITOR EFFECT AS ACTIVE INGREDIENT | HDAC1, HDAC9, HDAC5 | CASR 4152/4885EPHX2 4350/4885POLB 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.